Buscar
Mostrando ítems 1-1 de 1
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
(Taylor & Francis, 2014-07-07)
[Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel.
METHODS: This multi-centre ...